Literature DB >> 15861463

Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding.

Grayson Richards1, Jürg Messer, Pari Malherbe, Richard Pink, Manfred Brockhaus, Heinz Stadler, Jürgen Wichmann, Hervé Schaffhauser, Vincent Mutel.   

Abstract

Until recently, there was a lack of selective radioligands for the subtypes of metabotropic glutamate (mGlu) receptors. [(3)H]LY354740 ((+)-2-aminobicyclo[3,1,0]hexane-2,6-dicarboxylic acid), a selective agonist for group II receptors (mGlu2 and -3, which are negatively coupled to cAMP production), has now been used to map their brain distribution and abundance by in vitro binding and quantitative radioautography. The selective cation dependence of its binding allowed the discrimination between mGlu2 and mGlu3 receptor labeling. Thus, in the presence of Ca(2+) and Mg(2+) ions, the agonist bound selectively to mGlu2 receptors as evidenced by: 1) the correlative distribution and abundance of binding sites (highest in the lacunosum moleculare of the hippocampus and lowest in white matter) with mGlu2 receptor mRNA and protein revealed by in situ hybridization histochemistry and immunohistochemistry, respectively; 2) its selective pharmacology; and 3) the distribution of LY354740-stimulated [(35)S]GTPgammaS binding (25-97% above basal, according to the brain region), revealing G protein-coupled receptor coupling to G(i) proteins. Nonspecific binding (in the presence of 10 muM DCG-IV, a group II-selective, mGlu2-preferring, receptor agonist) was <10% of total. In adjacent sections, the distribution of binding sites for [(3)H]DCG-IV was very similar. This extensive study paves the way for investigations of the regional expression and regulation of mGlu2 receptors in human CNS diseases, such as Alzheimer's disease, which may reveal their functional roles and identify potential therapeutic drug targets. Indeed, it has recently been demonstrated (Higgins et al. [2004] Neuropharmacology 46:907-917) that pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15861463     DOI: 10.1002/cne.20538

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  14 in total

1.  Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking.

Authors:  Jennifer M Bossert; Sarah M Gray; Lin Lu; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2005-12-07       Impact factor: 7.853

2.  Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core.

Authors:  Katrina A Bollinger; Andrew S Felts; Christopher J Brassard; Julie L Engers; Alice L Rodriguez; Rebecca L Weiner; Hyekyung P Cho; Sichen Chang; Michael Bubser; Carrie K Jones; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2017-08-03       Impact factor: 4.345

3.  Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys.

Authors:  Zuzana Justinova; Bernard Le Foll; Godfrey H Redhi; Athina Markou; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2015-07-08       Impact factor: 4.530

Review 4.  Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction.

Authors:  Khaled Moussawi; Peter W Kalivas
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

5.  Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion.

Authors:  Alan L Pehrson; Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

6.  Group II metabotropic glutamate receptors in the striatum of non-human primates: dysregulation following chronic cocaine self-administration.

Authors:  T J R Beveridge; H R Smith; M A Nader; L J Porrino
Journal:  Neurosci Lett       Date:  2011-03-31       Impact factor: 3.046

7.  Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.

Authors:  Michael P Johnson; Mark A Muhlhauser; Eric S Nisenbaum; Rosa M A Simmons; Beth M Forster; Kelly L Knopp; Lijuan Yang; Denise Morrow; Dominic L Li; Jeffrey D Kennedy; Steven Swanson; James A Monn
Journal:  Br J Pharmacol       Date:  2017-03-13       Impact factor: 8.739

8.  Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.

Authors:  Xiaofei Zhang; Katsushi Kumata; Tomoteru Yamasaki; Ran Cheng; Akiko Hatori; Longle Ma; Yiding Zhang; Lin Xie; Lu Wang; Hye Jin Kang; Douglas J Sheffler; Nicholas D P Cosford; Ming-Rong Zhang; Steven H Liang
Journal:  ACS Chem Neurosci       Date:  2017-06-13       Impact factor: 4.418

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

10.  Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.

Authors:  Natalie Matosin; Francesca Fernandez-Enright; Elisabeth Frank; Chao Deng; Jenny Wong; Xu-Feng Huang; Kelly A Newell
Journal:  J Psychiatry Neurosci       Date:  2014-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.